RU2017120361A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2017120361A3 RU2017120361A3 RU2017120361A RU2017120361A RU2017120361A3 RU 2017120361 A3 RU2017120361 A3 RU 2017120361A3 RU 2017120361 A RU2017120361 A RU 2017120361A RU 2017120361 A RU2017120361 A RU 2017120361A RU 2017120361 A3 RU2017120361 A3 RU 2017120361A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192519 | 2014-11-10 | ||
| EP14192519.8 | 2014-11-10 | ||
| PCT/EP2015/075877 WO2016075036A1 (en) | 2014-11-10 | 2015-11-06 | Anti-pdgf-b antibodies and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017120361A RU2017120361A (ru) | 2018-12-13 |
| RU2017120361A3 true RU2017120361A3 (https=) | 2019-05-29 |
Family
ID=51947140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017120361A RU2017120361A (ru) | 2014-11-10 | 2015-11-06 | Антитела к pdgf-b и способы их применения |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10087246B2 (https=) |
| EP (1) | EP3218400A1 (https=) |
| JP (1) | JP6946184B2 (https=) |
| KR (1) | KR20170082520A (https=) |
| CN (1) | CN107148429B (https=) |
| AR (1) | AR102593A1 (https=) |
| AU (1) | AU2015345322A1 (https=) |
| BR (1) | BR112017009792A2 (https=) |
| CA (1) | CA2963723A1 (https=) |
| IL (1) | IL251286A0 (https=) |
| MX (1) | MX2017005975A (https=) |
| RU (1) | RU2017120361A (https=) |
| SG (1) | SG11201703426PA (https=) |
| TW (1) | TW201630934A (https=) |
| WO (1) | WO2016075036A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG175077A1 (en) | 2009-04-07 | 2011-11-28 | Roche Glycart Ag | Trivalent, bispecific antibodies |
| JP2017534644A (ja) | 2014-11-10 | 2017-11-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ａｎｇ２抗体及び使用方法 |
| BR112017009764A2 (pt) | 2014-11-10 | 2018-02-20 | Hoffmann La Roche | anticorpos biespecíficos e métodos de uso em oftalmologia |
| JP6787888B2 (ja) | 2014-11-10 | 2020-11-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ｉｌ−１ベータ抗体及び使用方法 |
| EP3227332B1 (en) | 2014-12-03 | 2019-11-06 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
| CA2992660A1 (en) * | 2015-07-29 | 2017-02-02 | Allergan, Inc. | Heavy chain only antibodies to ang-2 |
| EP3959242A4 (en) * | 2019-04-24 | 2023-09-13 | Magenta Therapeutics, Inc. | ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES |
| CN115397850A (zh) | 2020-03-30 | 2022-11-25 | 豪夫迈·罗氏有限公司 | 与vegf和pdgf-b结合的抗体及其使用方法 |
| CA3205846A1 (en) | 2021-01-25 | 2022-07-28 | Yinglin GAO | Anti-pdgf-b antibodies and mehods of use for treating pulmonary arterial hypertension (pah) |
| TW202540203A (zh) * | 2024-01-08 | 2025-10-16 | 日商中外製藥股份有限公司 | 結合pdgf-b與pdgf-d的抗原結合分子及使用方法 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935343A (en) | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
| EP1590369B1 (en) | 2003-01-24 | 2016-03-16 | Applied Molecular Evolution, Inc. | Human il-1 beta antagonists |
| NZ592039A (en) * | 2003-08-27 | 2013-03-28 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| WO2005087812A1 (en) * | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for vegf/pdgf family of growth factors |
| DE102004062361A1 (de) * | 2004-12-10 | 2006-06-22 | Cocreate Software Gmbh & Co. Kg | Verfahren zur Ableitung von technischen Zeichungen aus 3D Modellen mit mindestens zwei kollidierenden 3D Körpern |
| ZA200705695B (en) * | 2004-12-21 | 2009-02-25 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| WO2014001442A1 (en) | 2012-06-28 | 2014-01-03 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| SG11201408538PA (en) * | 2012-07-13 | 2015-02-27 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
| MX373894B (es) * | 2012-11-08 | 2020-07-09 | Clearside Biomedical Inc | Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos. |
| CA2890483A1 (en) * | 2012-11-09 | 2014-05-15 | Robert ARCH | Platelet-derived growth factor b specific antibodies and compositions and uses thereof |
| JO3405B1 (ar) * | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| UA118029C2 (uk) | 2013-04-29 | 2018-11-12 | Ф. Хоффманн-Ля Рош Аг | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування |
| RU2727639C2 (ru) | 2014-01-15 | 2020-07-22 | Ф.Хоффманн-Ля Рош Аг | Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а |
| BR112017009764A2 (pt) | 2014-11-10 | 2018-02-20 | Hoffmann La Roche | anticorpos biespecíficos e métodos de uso em oftalmologia |
| JP6787888B2 (ja) | 2014-11-10 | 2020-11-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ｉｌ−１ベータ抗体及び使用方法 |
| JP2017534644A (ja) | 2014-11-10 | 2017-11-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ａｎｇ２抗体及び使用方法 |
-
2015
- 2015-11-06 RU RU2017120361A patent/RU2017120361A/ru not_active Application Discontinuation
- 2015-11-06 EP EP15791586.9A patent/EP3218400A1/en not_active Ceased
- 2015-11-06 MX MX2017005975A patent/MX2017005975A/es unknown
- 2015-11-06 SG SG11201703426PA patent/SG11201703426PA/en unknown
- 2015-11-06 JP JP2017525016A patent/JP6946184B2/ja not_active Expired - Fee Related
- 2015-11-06 BR BR112017009792A patent/BR112017009792A2/pt not_active Application Discontinuation
- 2015-11-06 CN CN201580058634.5A patent/CN107148429B/zh not_active Expired - Fee Related
- 2015-11-06 WO PCT/EP2015/075877 patent/WO2016075036A1/en not_active Ceased
- 2015-11-06 CA CA2963723A patent/CA2963723A1/en not_active Abandoned
- 2015-11-06 KR KR1020177011693A patent/KR20170082520A/ko not_active Withdrawn
- 2015-11-06 AU AU2015345322A patent/AU2015345322A1/en not_active Abandoned
- 2015-11-09 TW TW104136908A patent/TW201630934A/zh unknown
- 2015-11-09 AR ARP150103646A patent/AR102593A1/es unknown
-
2017
- 2017-03-20 IL IL251286A patent/IL251286A0/en unknown
- 2017-05-09 US US15/590,172 patent/US10087246B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AR102593A1 (es) | 2017-03-08 |
| CA2963723A1 (en) | 2016-05-19 |
| CN107148429B (zh) | 2021-12-03 |
| KR20170082520A (ko) | 2017-07-14 |
| US20170247440A1 (en) | 2017-08-31 |
| JP6946184B2 (ja) | 2021-10-06 |
| RU2017120361A (ru) | 2018-12-13 |
| BR112017009792A2 (pt) | 2018-02-27 |
| CN107148429A (zh) | 2017-09-08 |
| SG11201703426PA (en) | 2017-05-30 |
| JP2017534645A (ja) | 2017-11-24 |
| WO2016075036A1 (en) | 2016-05-19 |
| AU2015345322A1 (en) | 2017-04-06 |
| EP3218400A1 (en) | 2017-09-20 |
| MX2017005975A (es) | 2017-06-29 |
| US10087246B2 (en) | 2018-10-02 |
| IL251286A0 (en) | 2017-05-29 |
| TW201630934A (zh) | 2016-09-01 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200326 |